Magnetic resonance imaging

A community portal about Magnetic resonance imaging with blogs, videos, and photos. According to Wikipedia.org: Magnetic Resonance Imaging , formerly referred to as Magnetic Resonance Tomography or, in chemistry, Nuclear Magnetic Resonance , is a method used to visualize the inside of living organisms as well as to detect the composition of geological structures. It is primarily used to demonstrate pathological or other physiological alterations of living tissues and is a commonly used form of medical imaging. MRI has also found many novel applications outside of the medical and biological fields such as rock permeability to hydrocarbons and certain non-destructive testing methods such as produce and timber quality characterization. The scanners used in medicine cost approximately $1 million USD per Tesla for each unit, with several hundred thousand dollars per year for maintenance. A man from Fraserburgh, Scotland, with terminal liver cancer become the first patient in the world to receive an MRI body scan in Aberdeen, U.K.

Write an Article

Join

RSS

Fwd: Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer.

Written by Dukkay on

From: mesotheliomadiagnosies.blogspot.com

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer.
To: mesothelioma77@gmail.com

[1]Cancer Epidemiol Biomarkers Prev. 2008 Jun 26;
Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, Zujewski JA, Prindiville S

BACKGROUND: Mammographic density is a risk factor for breast cancer. Mammographic density and breast magnetic resonance imaging (MRI) volume (MRIV) assess the amount of fibroglandular tissue in the breast. Mammographic density and MRIV can be modulated with hormonal interventions, suggesting that these imaging modalities may be useful as surrogate endpoint biomarkers for breast cancer chemoprevention trials. We evaluated the effect of raloxifene on mammographic density and MRIV in premenopausal women at increased risk for breast cancer.METHODS: Mammograms and MRI were obtained at baseline and after 1 and 2 years of 60 mg raloxifene by mouth daily for 27 premenopausal women. Mammographic percent dense area was calculated using a semiquantitative thresholding technique. T1-weighted spoiled gradient-echo MRI with fat suppression was used to determine breast MRIV using a semiautomatic method. Mean change in mammographic density and median change in MRIV were assessed by the Wilcoxon signed-rank test.RESULTS: No significant change in mammographic density was seen after treatment with raloxifene. Mean change after 1 year was 1% [95% confidence interval (95% CI), -3 to +5] and after 2 years was 1% (95% CI, -2 to +5). MRIV decreased on raloxifene. Median relative change in MRIV after 1 year was -17% (95% CI, -28 to -9; P = 0.0017) and after 2 years was -16% (95% CI, -31 to -4; P = 0.0004).CONCLUSIONS: In high-risk premenopausal women, mammographic density did not change on raloxifene, whereas MRIV significantly declined. Our findings suggest that MRIV is a promising surrogate biomarker in premenopausal women at increased risk for breast cancer and should be investigated further in breast cancer prevention trials. (Cancer Epidemiol Biomarkers Prev 2008;17(7):OF1-6).

___
Source: http://www.hubmed.org/display.cgi?uids=18583470
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

	Camera Buying Tips A picture is worth a thousand words, but not all cameras are worth a thousand bucks.
	10 Places to Get FREE Images for your Blog Gotta love the word "Free".
	Astronomy Picture Of The Day This picture makes us feel very very small.